News >

Addressing Questions Left Unanswered by PACIFIC in Stage III NSCLC

Caroline Seymour
Published: Tuesday, May 21, 2019

Lyudmila A. Bazhenova, MD
Lyudmila A. Bazhenova, MD
Consolidative therapy with durvalumab (Imfinzi) after concurrent chemoradiation resulted in a significant survival benefit in patients with unresectable stage III non–small cell lung cancer (NSCLC). Although additional studies have provided further insight on responses per PD-L1 expression and the optimal timing of durvalumab, there are many outstanding questions that need to be addressed, explained Lyudmila A. Bazhenova, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x